News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Imatinib mesylate in clinically suspected gastric stromal tumors.
|Title||Imatinib mesylate in clinically suspected gastric stromal tumors.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Li Z-Y, Tang L, Li S-X, Shan F, Bu Z-D, Ji J-F|
|Journal||Chinese journal of cancer research = Chung-kuo yen cheng yen chiu|
|Date Published||2013 Oct|
Gastrointestinal stromal tumors (GISTs) occur most frequently in the stomach. Diagnosis of gastric GIST is not always clear before surgery. Flexible endoscopy may suggest the nature of the lesion (a bulky tumor with preserved mucosa); however, biopsy is rarely diagnostic. Therefore, diagnostic medication with safe drugs may provide a feasible way under such conditions after an informed consent is obtained. Based on the excellent efficacy of imatinib mesylate (IM) in the treatment of GIST, we successfully applied it in the diagnostic medication of two patients with clinically suspected gastric stromal tumors. In conclusion, the diagnostic medication with IM can be an alternative option for patients with suspected GIST that can not be confirmed pathologically.
|Alternate Journal||Chin. J. Cancer Res.|